Repeated administration of non-immunosupressive antigen specific immunotherapeutics

A technology for immunotherapy and immunosuppression, applied in anti-inflammatory agents, antibody medical ingredients, specific peptides, etc.

Pending Publication Date: 2021-06-11
SELECTA BIOSCI
View PDF43 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Additionally, to maintain immunosuppression, immunomodulator drug therapy is generally a life-long problematic issue
Unfortunately, the use of broad-acting immunomodulators is associated with a risk of serious side effects such as tumors, infections, nephrotoxicity and metabolic disturbances

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Repeated administration of non-immunosupressive antigen specific immunotherapeutics
  • Repeated administration of non-immunosupressive antigen specific immunotherapeutics
  • Repeated administration of non-immunosupressive antigen specific immunotherapeutics

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0250] Example 1: Demonstration of a non-immunosuppressive regimen using repeatedly administered antigen-specific immunotherapeutics Materials for Synthesizing Nanocarriers

[0251] Rapamycin was purchased from TSZ CHEM (185 Wilson Street, Framingham, MA01702; catalog #R1017). PLGA of approximately 25,000 Da was purchased from Lakeshore Biochemicals (756 Tom Martin Dr Birmingham, AL 35211). Product code 5050 DLG 2.5A. A PLA-PEG-OMe block copolymer with a methyl ether terminated PEG block of about 5000 Da and a PLA block of about 48,000 Da was purchased from Lakeshore Biochemicals (756 Tom Martin Drive, Birmingham, AL 35211). Product code 100DL mPEG 5000 5CE. OPII.323 was purchased from BACHEM (3132 Kashiwa Street, Torrance, CA 90505; lot #B06481). Polyvinyl alcohol 4-88, USP (85% to 89% hydrolyzed, viscosity 3.4 mPa.s to 4.6 mPa.s) was purchased from EMD Chemicals Inc. (480 South Democrat Road Gibbstown, NJ 08027. Product No. 1.41354).

[0252] Methods of Synthesizing N...

Embodiment 2

[0283] Example 2: PLP-conjugated tolerogenic synthetic nanocarriers utilizing repeatedly administered endogenous antigens (predicted sexual)

[0284] PLP-conjugated synthetic nanocarriers were prepared according to the method shown in Example 21 of Published US Patent Application 2012 / 0076831 by Miller et al. ("Miller"). On day 0, synthetic nanocarriers were administered initially intravenously to SJL mice at a dose of 10 mg nanocarriers / kg body weight, and then repeated intravenously every two weeks for 6 weeks after the initial administration. Blood samples were collected on day 0, immediately prior to each repeat dose, and one week after the last repeat dose.

[0285] Blood samples were analyzed to establish KLH IgG titers using the KLH IgG ELISA method as generally described in Example 1 above. The absence of immunosuppression can be noted as evidenced by KLH IgG titers above background in one or more samples taken after repeated administration of synthetic nanocarrie...

Embodiment 3

[0287] Example 3: Nanogel-type Tolerogenic Synthetic Nanocarriers Using Repeatedly Administered Endogenous Antigens (Prophetic sexual)

[0288] According to the method disclosed in M. Look et al. "Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice" J Clin Invest.doi: 10.1172 / JCI65907 (2013), the nanogel type synthetic nanocarrier containing mycophenolic acid was prepared. C57BL / 6 mice were initially administered daily intravenous administration of the synthetic nanocarriers at a dose of 0.625 mg MPA / kg animal body weight ("mpk") for 4 days, followed by monthly repeated intravenous administration of 6 doses after the initial administration. moon. Blood samples were collected on day 0, immediately before each repeat dose, and one week after the last repeat dose.

[0289]Blood samples were analyzed to establish KLH IgG titers using the KLH IgG ELISA method as generally described in Example 1 above. The absence of immunosuppression c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

This invention relates to repeated administration of non-immunosupressive antigen specific immunotherapeutics, and relates to repeated administration of antigen- specific immunotherapeutics using protocols, or elements thereof, that do not induce immunosuppression. In some embodiments, the protocol has been previously shown not induce immunosuppression in a subject.

Description

[0001] This application is a divisional application of the Chinese patent application with application number 201480031689.2. The original application is the PCT international application PCT / US2014 / 040938 filed on June 4, 2014, which entered the Chinese national phase on December 2, 2015. [0002] related application [0003] This application claims the benefit under 35 U.S.C. §119 of U.S. Provisional Application 61 / 831,128, filed June 4, 2013, the entire contents of which are incorporated herein by reference. technical field [0004] The present invention involves repeated administration of antigen-specific immunotherapeutics using a protocol or elements thereof that do not induce immunosuppression. In some embodiments, the regimen has been previously shown not to induce immunosuppression in the subject after repeated administration. Background technique [0005] Certain diseases or conditions that require protein or enzyme replacement therapy (such as autoimmune diseases...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K39/00A61P37/02
CPCA61K9/127A61K9/5153C07K14/4713A61K39/001A61K39/39A61K2039/53A61K2039/545A61K2039/55555A61K2039/6093A61K47/60A61K47/593A61K47/646A61K47/6903A61K47/6923A61K47/6933A61K47/6935A61K47/6937A61K38/13A61P1/04A61P1/16A61P1/18A61P13/12A61P15/08A61P17/00A61P17/04A61P17/06A61P17/14A61P19/02A61P19/08A61P21/00A61P21/04A61P25/00A61P27/02A61P29/00A61P35/00A61P37/00A61P37/02A61P37/06A61P5/14A61P7/00A61P7/06A61P9/00A61P3/10C07K16/18C07K2317/21C07K2319/00C07K14/575
Inventor 罗伯托·A·马尔多纳多岸本·隆·慧
Owner SELECTA BIOSCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap